Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11827902 End-to-end cell therapy automation

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Nuala Trainor0

Ann Siehoff0

Timothy Smith0

Eytan Abraham0

Erika McAfee0

Timo Gleissner0

Samatha Bandapalle0

Kelly Purpura0

...

Date of Patent

November 28, 2023

0

Patent Application Number

177519990

Date Filed

May 24, 2022

0

Patent Citations

US Patent 8492140 Automated tissue engineering system

0

US Patent 8727132 Sample processing system and methods

0

US Patent 9499780 Advanced tissue engineering system

0

US Patent 9534195 Automated tissue engineering system

0

US Patent 9629877 Human application of engineered chimeric antigen receptor (CAR) T-cells

0

US Patent 9701932 Automated tissue engineering system

0

US Patent 9783768 Automated cell culture system

0

US Patent 10131876 Method for automated generation of genetically modified T cells

0

...

Patent Primary Examiner

0

Patent abstract

The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11827902 End-to-end cell therapy automation

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool